Volociximab

Phase 2Monoclonal antibody

AbbVie

Volociximab is one of 210 small molecule programs targeting Macular Degeneration. It is currently in Phase 2.

Indications

Total Trials

Active Trials

209

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular DegenerationActive, not recruiting

Metastatic MelanomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Macular DegenerationPhase 1

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Volociximab

AbbVie

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Ofev

Boehringer Ingelheim

Preclinical

7 5

Remeron

OOrganon and Co

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

REGN2810

Regeneron

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Terminated·FFacet Biotech·Phase 2·NCT00516841·16 enrolled

Macular Degeneration1 trial

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Completed·OOphthotech Corporation·Phase 1·NCT00782093·63 enrolled

Non-Small Cell Lung Cancer1 trial

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown status·JJonsson Comprehensive Cancer Center·Phase 2·NCT00278187

Renal Cell Carcinoma1 trial

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Terminated·AAbbott·Phase 2·NCT00100685·48 enrolled

Pancreatic Cancer1 trial

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT00401570·40 enrolled

1 more indication

Metastatic Melanoma1 trial

A Study of Volociximab in Metastatic Melanoma

Terminated·AAbbott·Phase 2·NCT00369395·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Volociximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Volociximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Volociximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Volociximab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Macular Degeneration1 trial

Non-Small Cell Lung Cancer1 trial

Renal Cell Carcinoma1 trial

Pancreatic Cancer1 trial

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News